Introduction
In addition to chronic myeloid leukemia, the Philadelphia (Ph 1 ) chromosome is also detected in 20-40% of acute lymphoblastic leukemia (ALL), a poor-prognosis disease subtype. 1 The Ph 1 chromosome is the result of the t(9;22) reciprocal translocation, which generates three BCR/ABL fusion genes each containing different 5 0 portions of BCR fused to exons 2-11 of ABL, with the breakpoint in BCR determining size, activity of the gene product and disease phenotype. 2 p190 BCR/ABL is the result of head-tail fusion of BCR exon-1 with ABL exon-2 (e1-a2 fusion) and encodes a 7.0-kb mRNA, which is translated into a 190-kDa protein with constitutive tyrosine kinase activity, the highest among the three forms of BCR/ABL. 3, 4 Mechanisms implicated in BCR/ABL-dependent transformation of hematopoietic cells include activation of the RAS, STAT5 and phosphatidylinositol-3-OH kinase pathways, which provide proliferative and anti-apoptotic signals thought to be essential for the process of leukemogenesis. [5] [6] [7] These pathways are activated by all BCR/ABL variants; 8 however, certain pathways are activated by p190 BCR/ABL in a B-cell-specific manner, [9] [10] [11] possibly accounting for its distinct role in B-cell transformation.
Expression of p210 BCR/ABL induces also changes in the levels and activity of several transcription factors; besides members of the STAT family, p210 BCR/ABL enhances the expression of c-Myc 12 and the activity of the B-catenin/LEF-1 and the Hedgehog pathways, both of which may regulate the selfrenewal of normal and BCR/ABL-transformed mouse and human progenitor subsets. [13] [14] [15] BCR/ABL can also repress the expression of C/EBPa and JunB, two transcription factors causally linked to development of leukemia and myeloproliferative disorders in mice and humans. [16] [17] [18] Expression of c-Myb is also regulated by p210 BCR/ABL , 19 and AML and chronic myeloid leukemia blasts rely on its expression for proliferation and survival more than the normal counterpart. 20, 21 Using a genetic approach, we recently demonstrated that optimal levels of c-Myb are required for p210 BCR/ABLdependent transformation of hematopoietic progenitors and leukemogenesis. 22 Duplication or translocation of the c-Myb gene has recently been identified in a cohort of pediatric T-cell acute lymphocytic (T-ALL) patients, 23, 24 and knockdown of c-Myb expression in T-ALL cell lines promoted differentiation, 23 suggesting that it may have a pathogenic role at least in a subset of T-ALL patients. Less is known about the role of c-Myb in B-cell acute lymphocytic leukemia (B-ALL) and in mouse models of B-cell leukemia. Using in vivo and in vitro assays of p190 BCR/ABL -dependent leukemogenesis and transformation of B-cell progenitors, we show here that c-Myb-hemizygous B-cells are less leukemogenic and clonogenic than the normal counterpart. Downregulation of c-Myb expression also reduced proliferation and cluster formation of the human p190 BCR/ABL Z-181 and SUP-B15 B-ALL cell lines. By hybridization of oligonucleotide arrays with RNA from p190 BCR/ABL /Myb þ /À pre-B cells, we identified differentially expressed genes with potential roles in B-cell leukemogenesis. One such gene, the hematopoietic stem cell regulator Bmi1, 25 is a direct transcriptional target of c-Myb. Ectopic expression of Bmi1 rescued the defective colony-forming potential of p190 BCR/ABL / Myb w/d B cells; by contrast, knockdown of Bmi1 expression suppressed the colony formation of p190 BCR/ABL -expressing Myb w/w murine B cells and human ALL cells. Expression of c-Myb and Bmi1 was correlated in blast cells from 19 BCR/ABLpositive adult ALL patients.
Together, these studies suggest that c-Myb regulates the process of p190 BCR/ABL -dependent B-cell leukemogenesis, at least in part, through its effect on the levels of Bmi1; as Bmi1 is involved in stem cell self-renewal, c-Myb-regulated abnormal expression of Bmi1 might represent an important mechanism for transformation and maintenance of p190 BCR/ABL -expressing pre-B cells.
Materials and methods

Mice
Myb f/f and Myb f/d mice 26 were maintained by brother-sister mating. C57BL/6J mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). ICR-SCID mice were obtained from Taconic (Hudson, NY, USA). B6;CBA-Tg(BCR-ABL) 623Hkp mice were obtained from the NCI Mouse Repository. 27 BCR-ABL þ Myb w/f and BCR-ABL þ Myb w/d mice were generated through crosses of B6;CBA-Tg(BCR-ABL) 623Hkp and Myb f/d mice. Strains were genotyped as described. 26, 27 Experiments were performed according to the Animal Care and Use Committee's guidelines.
Plasmids
MSCVp190wt-IRES/eGFP (MigRI-p190) was provided by Dr Richard Van Etten (Tufts University, Boston, MA, USA). MigRI-D(358-452) c-Myb-GFP was described previously. 19 MSCV Bmi1-IRES-eYFP was obtained by removing full-length Bmi1 from the MSCV-Bmi1-pgk-EGFP plasmid provided by Dr Guy Sauvageau (Clinical Research Institute of Montreal, Montreal, QC, Canada) and cloning it at the EcoRI-XhoI sites of the MSCV vector. Two pLKO.1-based lentiviral short-hairpin (shRNA) vectors, TRCN0000040058 and TCRN0000012565 (Open Biosystems, Huntsville, AL, USA), were used for Myb and Bmi1 knockdown, respectively. A scrambled lentiviral shRNA (#1864; Addgene, Cambridge, MA, USA) was used as control. pLVTSH-Myb, which encodes a doxycycline-inducible c-Myb shRNA targeting nucleotides 1161-1187 (from the AUG start site) of the human c-Myb mRNA, was provided by Dr Thomas Gonda (University of Queensland, Queensland, Australia).
Culture conditions, isolation and retroviral/lentiviral transduction of bone marrow cells
Bone marrow cells were isolated from the femurs of Myb f/d , Myb f/f , BCR-ABL þ Myb w/f and BCR-ABL þ Myb w/d mice, and non-nucleated cells were removed by hypotonic lysis. Prior to transduction, Myb f/f and Myb f/d marrow cells were cultured in pre-stimulation media with murine interleukin-7 (IL-7). 10 Retroviral transductions were performed as described by Lidonnici et al. 22 Lentiviral transduction was performed by using concentrated supernatant (Marino PB et al, 2003) from 293T cells co-transfected with the pLKO.1shRNA vector, pMDG and pCMVDR874 plasmids. Lentiviral stocks were titrated on K562 cells using a 10 À2 -10 À7 dilution. Viral transduction was performed at a cell density of 2 Â 10 5 cells/ml. Transduced cells were plated at 1 Â 10 5 cells/ml in the presence of puromycin (2 mg/ml). The percentage of cells surviving after 2 days of selection was used to calculate viral titer. Approximately 1.1 Â 10 9 infectious units per milliliter were used in lentiviral transduction experiments. One round of co-sedimentation and incubation was performed as described above.
Bone marrow transplantation and leukemogenesis assays 2 Â 10 6 BCR-ABL-transduced Myb f/f and Myb f/d bone marrow cells were transplanted into lethally irradiated (11 Gy in two split doses of 5.5 Gy each) C57BL/6J mice by tail-vein injection.
The presence of green fluorescent protein (GFP)-positive, BCR/ ABL-expressing cells in the bone marrow and spleen was evaluated by flow cytometry. For determination of survival, mice appearing moribund were killed and the bone marrow and spleen were harvested for immunophenotyping of p190BCR/ ABL-transduced GFP þ cells.
Flow cytometry and immunophenotyping
Bone marrow and spleen single-cell suspensions from transplanted mice were evaluated for GFP positivity using normal bone marrow and splenocytes as control. The lineage of GFP-positive cells was determined by using phycoerythrin (PE)-Cy5-anti-mouse CD19 (Biolegend, San Diego, CA, USA) and PE-anti-mouse Gr-1 (BD Pharmingen, San Diego, CA, USA). Immunophenotyping of B cells was performed using the anti-mouse antibodies APC-B220 (Biolegend), PE-CD43 (BD Pharmingen) and fluorescein isothiocyanate (FITC)-IgM (BD Pharmingen).
Colony formation assay
Bone marrow cells from BCR-ABL þ Myb w/f and BCR-AB-L þ Myb w/d mice were plated in 'Complete' Methylcellulose Medium at 50 000 cells per plate for Pre-B-Cell Colony Assays (Stem Cell Technology, Vancouver, Canada). Cells transduced for knockdown or overexpression experiments were plated at 100 000 cells per plate. Colonies were scored after 7-11 days.
RNA interference
For short interfering RNA (siRNA) transfection, 1 Â 10 6 Z-181 or SUP-B15 cells were resuspended in 100 ml of nucleofector V solution (Amaxa, Cologne, Germany) and mixed with 5 mg of ON-TARGET plus SMART pool siRNA (Thermo Fisher Scientific, Dharmacon, Waltham, MA, USA). The solution was poured into Amaxa electrode cuvettes and electroporated in an Amaxa Electroporator II, using the program S-18 (Z-181) or X-01 (SUP-B15). Afterward, cells were diluted in 2 ml of Iscove's Modified Dulbecco Medium (IMDM) (supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin and 2 mM L-glutamine) at 37 1C (5 Â 10 5 cells/ml).
ChIP assays
Chromatin immunoprecipitation (ChIP) assays were performed by using the ChIP Assay Kit (USB Corporation, Cleveland, OH, USA). Briefly, 2.5 Â 10 7 exponentially growing Z-181 cells were cross-linked with 1% formaldehyde, incubated for 10 min at 37 1C and treated with glycine (final concentration125 mM; 5 min at room temperature). Cells were then washed with icecold phosphate-buffered saline and resuspended in 1 ml of lysis buffer with a protease inhibitor cocktail and sonicated at 30% power for 20 pulses of 15 s each in a Branson Sonifier 450 (Branson Ultrasonics, Danbury, CT, USA). Chromatin was precleared with 50 ml of protein-A-agarose beads for 60 min at 4 1C with rotation and pre-cleared lysates were immunoprecipitated with the anti c-Myb antibody (8 mg, clone 1-1; Upstate Biotechnology, Lake Placid, NY, USA) at 4 1C overnight with rotation. Immunoprecipitations without antibody (no antibody control) or an anti-mouse IgG (8 mg; Thermo Scientific Pierce, Rockford, IL, USA) were included with each experiment. Immune complexes were collected with 50 ml of protein-Aagarose beads for 60 min at 4 1C with rotation (except for 10 ml of supernatant of the no antibody control saved as input) and washed once with 1 ml each of low-salt wash buffer (0.1% c-Myb expression and p190BCR/ABL transformation T Waldron et al sodium dodecyl sulfate , 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0) and 150 mM NaCl), high-salt wash buffer (0.1% sodium dodecyl sulfate, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0) and 1.5 M NaCl), LiCl wash buffer (250 mM LiCl; 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA and 10 mM Tris-HCl (pH 8.0)), and twice with 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA. Immune complexes were next eluted using freshly prepared elution buffer (1% sodium dodecyl sulfateand 0.1 M NaHCO 3 ). Cross-links were reversed by heating at 65 1C overnight in the presence of 0.2 M NaCl. DNA was recovered by using the PrepEase DNA Clean-Up Kit (USB Corporation). ChIP DNA (2 ml) was used as a template for semi-quantitative PCR (32 cycles) using the following Bmi-1 primers: (sense: 5 0 -ACGGGCCTGACTACACC GACACT-3 0 , antisense 5 0 -CCCGATCTCTGCCTCTCATA-3 0 from À238 to þ 23), (sense 5 0 -GTTTCCACTCTGCCTTCAGC-3 0 , antisense 5 0 -CCCGATCTCTGCCTCTCATA-3 0 , from À111 to þ 23) and (sense 5 0 -AGAGAGATGGACTGACAAATGC-3 0 , antisense 5 0 -GTGAGGAAACTGTGGATGAGG-3 0 from þ 5954 to þ 6103).
Patients
The levels of c-Myb and Bmi1 mRNA were analyzed in the peripheral blood or bone marrow blasts of 19 newly diagnosed BCR-ABL1-positive adult ALL patients. Diagnosis of ALL was made on the basis of the morphological, biochemical and immunological characteristics of leukemic cells. Patients' median age was 53 years (range: 18-76) and median blast percentage at diagnosis was 90% (range: 49-99). The main characteristics of the patients are shown in Supplementary Table 2 .
Reverse transcription-PCR analysis of c-Myb and Bmi1 expression in patient samples
Total RNA was extracted from mononuclear cells separated by Ficoll-Hypaque density-gradient centrifugation by using the RNeasy total RNA isolation kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions; 1 mg of RNA was used for cDNA synthesis using Moloney murine leukemia virus reverse transcriptase (Invitrogen, Carlsbad, CA, USA) in the presence of dNTPs and Random Hexamer primers (Perkin-Elmer, Vaterstetten, Germany).
MYB and BMI1 expression was assessed by using the SYBR Green PCR master Mix (Applied Biosystems, Foster City, CA, USA) and the primers described in Supplementary Table 3 . Taqman SYBR Green assays were performed in duplicate using a 7900 Real-Time PCR system and the 7900 System Software (Applied Biosystems) and a thermal protocol consisting of 50 1C for 2 min, followed by 95 1C for 10 min, then 40 cycles of 95 1C for 1 min and 60 1C for 1 min. Results were normalized to the level of the ubiquitously expressed glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Standard curves were generated for experiments measuring absolute (copy number) expression values and the results were expressed as the ratios MYB/GAPDH and BMI1/GAPDH.
Statistical analyses
Owing to the small sample size, exact methods were used for survival analyses by using StatXact version 8 by Cytel (Cambridge, MA, USA). The Wilcoxon-Gehan test for censored data was computed for each study. The Wilcoxon-Gehan test is similar to the log-rank test for survival data, but it assigns a higher weight to early observations and gradually reduces the weight over time. Kaplan-Meier plots were generated using the R software (Lucent Technologies, now Alcatel-Lucent, Paris, France). All P-values reported are based on exact two-sided tests. All other statistical analyses were conducted by using unpaired Student's t-test.
Results
Frequency of B-cell subsets in heterozygous c-Myb-knockout mice
To test the requirement of c-Myb in normal B cells and in p190 BCR/ABL -dependent leukemogenesis, we used heterozygous c-Myb-knockout mice (referred here as Myb f/d ) because deletion of both Myb alleles induces a marked decrease of mature B cells by a block at the pro-B-to-pre-B transition. 28 We first assessed whether loss of a c-Myb allele correlated with reduced c-Myb expression in marrow mononuclear and CD19 þ B cells. Compared with cells with two functional Myb alleles (Myb f/f ), the levels of c-Myb were reduced approximately 50% in both cell fractions from mice with only one functional Myb allele (Myb f/d ) (Supplementary Figure 1A) .We then assessed the frequency of B-cell subsets; consistent with previous studies using adult mice on a mixed genetic background, 26 Figure 1B ). Figure 1E ) showed minor, but not significant, differences (P ¼ 0.280 and 0.310, respectively).
Myb f/f and Myb f/d bone marrow cells have a similar capacity to reconstitute B-cell subsets in recipient mice
Requirement of c-Myb in two models of p190BCR/ ABL-dependent leukemogenesis
We first assessed whether c-Myb expression is necessary for p190 BCR/ABL -dependent leukemogenesis by using bone marrow cells from Myb f/f and Myb f/d mice transduced with the MigRI/ GFP-p190 BCR/ABL retrovirus and transplanted into lethally irradiated recipient mice. Transplanted mice (6 per group) were killed 8 weeks after injection; mice injected with Myb f/f cells showed extensive infiltration of GFP-positive cells into the bone marrow and spleen; by contrast, mice transplanted with Myb f/d bone marrow cells had very few GFP-positive cells in these tissues (Figure 1a ). Nearly all GFP-positive cells in the bone marrow and spleen of Myb f/f -recipient mice were CD19 þ (Figure 1a and injected into sub-lethally irradiated recipient mice. Two mice each were transplanted with 2.5 Â 10 5 , 5 Â 10 4 or 1 Â 10 4 pro-B cells. Within 18 days, all secondary recipient mice became moribund and were killed. Each showed massive infiltration of the bone marrow and spleen with p190 BCR/ABLtransduced GFP-positive cells (Figure 1b ). To further assess whether the pro-B-cell leukemia was transplantable, tertiary recipient mice were injected with GFP þ CD19 þ CD43 þ cells sorted from secondary recipients. As few as 100 cells were sufficient to cause leukemia within 24 days of injection (data not shown).
To determine whether the reduced infiltration of GFP-positive leukemic cells in mice transplanted with p190 BCR/ABLtransduced Myb f/d bone marrow cells correlated with longer survival, mice injected with p190 BCR/ABL -transduced bone marrow cells from Myb f/f and Myb f/d mice were killed when terminally ill and the bone marrow and spleen evaluated by flow cytometry for the presence of GFP-positive leukemic cells. The median survival of mice (n ¼ 12) transplanted with p190 BCR/ABLtransduced marrow cells from Myb f/f mice was 56 days, whereas that of mice (n ¼ 14) inoculated with p190 BCR/ABL -transduced marrow cells from Myb f/d mice was 130 days (Figure 1c) . The difference in survival of the two groups was statistically significant (P ¼ 0.007; log-rank test).
The reduced leukemogenic potential of p190 BCR/ABLtransduced Myb f/d marrow cells was rescued by co-infection with a retrovirus encoding a mutant form of c-Myb: mice (n ¼ 5)
injected with doubly transduced Myb f/d marrow cells survived even less of those injected with p190 BCR/ABL -transduced Myb f/f marrow cells (Figure 1c ). GFP þ cells taken from the bone marrow and spleen of leukemic mice showed a pro-B-cell phenotype (Figure 1d) .
The role of c-Myb expression in p190 BCR/ABL -dependent leukemogenesis was also assessed using intercrosses of p190 BCR/ABL transgenic mice, which typically develop a B-cell leukemia, 28 (Figure 2a ). Hematopoietic tissues of moribund mice were infiltrated with B220 þ CD43 low/À IgM À cells, whereas only few GR-1-positive myeloid cells were detected (Figure 2b Table 1 ). The reduced colony formation of BCR/ABL þ Myb w/d pre-B cells was rescued by expression of a mutant form of c-Myb with a longer half-life 19 (Supplementary Figures 3A and B ). Supplementary Figures 4A and B) . Known c-Mybregulated genes such as Bcl-2, c-Kit, Rag2, adenosine receptor-2B (activated) and GATA-2 (repressed) showed lower or higher expression in total RNA from BCR/ABL þ Myb w/d pre-B cells; additional potential c-Myb targets with a possible involvement in transformation include members of the WNT/b-catenin family and the polycomb group gene Bmi1. We decided to investigate Bmi1 further because of its role in hematopoietic stem cell selfrenewal and leukemogenesis. 25 Bmi1 mRNA expression is lower (P ¼ 0.0396) in BCR/ABL þ Myb w/d than in BCR/ ABL þ Myb w/f pre-B cells (Figure 3a , and Supplementary  Figures 4A and B) and correlates with reduced protein levels (approximately 40% by densitometry) (Figure 3b ).
c-Myb-regulated Bmi1 expression is required for p190 BCR/ABL -dependent leukemogenesis
To evaluate whether Bmi1 is required for p190 BCR/ABLdependent transformation, its expression was knocked down in BCR/ABL þ Myb w/f bone marrow cells lentivirally transduced with a pre-tested Bmi1 shRNA (Figure 3c ). Bmi1 shRNAtransduced BCR/ABL þ Myb w/f bone marrow cells (from an 8-week-old mouse) showed significant reduction in pre-B colony formation compared with empty vector (EV)-transduced cells (P ¼ 0.001) (Figure 3d ).
We also overexpressed Bmi1 in BCR/ABL þ Myb w/d bone marrow through retroviral transduction and transduced cells were used for colony formation assays. Upon plating on IL-7-supplemented methylcellulose plates, Bmi1-transduced bone marrow cells were markedly more clonogenic than (Figure 4a ). Because Bmi1 can promote B-cell transformation, 29 we transduced BCR/ ABL À Myb w/d bone marrow cells with the Bmi1 or the control vector to assess whether expression of Bmi1 alone was sufficient to increase colony numbers. As expected, expression of Bmi1 alone did increase the number of IL-7-dependent colonies (P ¼ 0.017) ( Figure 4a) ; however, colonies were significantly fewer than those derived from cells co-expressing BCR/ABL and Bmi1 (Po0.001) (Figure 4a ), suggesting that Bmi1 cooperates with p190 BCR/ABL in B-cell transformation. As Bmi1 promotes the self-renewal of normal and leukemic hematopoietic stem cells, 28 
Bmi1 is a direct c-Myb target
Because reduced c-Myb expression correlated with lower Bmi1 levels (Figures 3a and b) , we investigated whether expression of Bmi1 was directly regulated by c-Myb.
A search of the murine and human Bmi1 promoter using transcription factor-binding-site databases (that is, www. gene-regulation.com) indicated the presence of putative Mybbinding sites, suggesting that Bmi1 might be a direct Myb target.
Using a human Bmi1 5 0 flanking sequence-LUC plasmid, 30 we performed luciferase assays in 293T cells co-transfected with the MigRI EV or the MigRI-Myb full-length cDNA. In three independent experiments, Bmi1-driven LUC activity was transactivated approximately two-fold (Supplementary Figure  5A , top panel, left); a similar effect was observed using the Bmi1-LUC plasmid with a mutated c-Myc-binding site 30 ( Supplementary Figure 5A, top panel, right) ; as c-Myc has been reported to be a c-Myb target, 31 the effect of Myb on the Bmi1 promoter might be direct. ChIP assays performed in the Ph 1positive Z-181 B-cell leukemia line 32 demonstrated that the À238 to þ 43 or the À111 to þ 43 segment of the Bmi1 5 0 flanking region (but not nucleotides þ 5954 to þ 6103 in the coding sequence) was amplified from anti-c-Myb ChIP assays (Supplementary Figure 6C ), suggesting that the interaction occurs in correspondence of the underlined putative c-Mybbinding site at nucleotides þ 3 to þ 8 (Supplementary Figure  6B) . To assess the role of this putative binding site, an Mybbinding-mutant 5 0 Bmi1-Luc plasmid was generated and used in promoter transactivation assays. The promoter with a mutated Myb-binding site was no longer transactivated by c-Myb (Supplementary Figure 5, bottom, right) , whereas the corresponding wild-type promoter showed a twofold transactivation ( Supplementary Figure 5, bottom, left) . Figure 6 ). Downregulation of Myb expression was associated with decreased levels of Bmi1 (approximately 50% and 25% in siRNA-transfected Z-181 and SUP-B15 cells, and 50% and 75% in shRNA-transduced Z-181 and SUP-B15 cells, respectively) (Figures 5a and b, and Supplementary Figure 7) . We also assessed the proliferation and colony formation of Bmi1 siRNA-transfected Z-181 and SUP-B15 cells; both cell lines proliferated less and formed fewer colonies (Po0.05 and Po0.002, respectively) than the scramble siRNA-transfected counterpart (Figures 5c-f) ; of interest, inhibition of colony formation was more pronounced than inhibition of proliferation.
c-Myb and Bmi1 expression shows a positive correlation in BCR-ABL1 þ ALL patients
Expression of c-Myb and Bmi1 mRNA was assessed in the blast cells of 19 newly diagnosed BCR-ABL1-positive adult ALL patients (Figures 6a and b) . The median value of the Myb/ GAPDH ratio in the ALL blasts was 4.46 (range, 1.43-19.9), whereas the median value of the Bmi1/GAPDH ratio was 2.835 (range, 1.12-24.57). Overall, expression of c-Myb and Bmi1 showed a trend toward positive correlation when considering the totality of the ALL samples (P ¼ 0.0478; Spearman correlation analysis). The correlation in the ALL group was even stronger when limiting the analysis to the p190 BCR/ABL -positive samples (P ¼ 0.0132) (Figure 6c ).
Discussion
In this study, we investigated the role of c-Myb in B-cell leukemogenesis induced by p190 BCR/ABL because, in spite of its essential role in B-cell development and its abundant expression in B-ALL (including few cases of Ph 1 ALL), 33, 34 no data exist in support of an important role of c-Myb in models of oncogeneinduced B-cell malignancies.
We used (i) lethally irradiated mice transplanted with wild-type (f/f) or Myb þ /À (f/d) marrow cells transduced with the p190 BCR/ABL retrovirus, and (ii) 190 BCR/ABL transgenic mice intercrossed with knockout mice carrying one functional c-Myb allele (w/d).
In both models, reduced c-Myb expression caused longer disease latency and survival of leukemic mice. In the bone marrow transplantation/leukemogenesis model, p190 BCR/ABL induced a pro-B-cell leukemia (CD19 þ CD43 þ ) whereas p190 BCR/ABL transgenic mice developed a leukemia with a predominant pre-B-cell (B220 þ CD43 low/À IgM À ) phenotype; pre-B cells from p190 BCR/ABL /Myb w/d transgenic mice were less clonogenic than the Myb w/f counterpart, suggesting that optimal levels of c-Myb are required for proliferation and survival of p190 BCR/ABL -transformed pre-B cells. Direct proof that this effect is specific for p190 BCR/ABL -transformed cells stems from the observation that no differences in colony formation were noted using Myb w/f and Myb w/d pre-B cells from p190 BCR/ABL -negative littermates. To address potential mechanisms that may explain the selective effect of c-Myb dosage in p190 BCR/ABL -transformed cells, we performed microarray analyses using RNA from p190 BCR/ABL -expressing and normal Myb w/f and Myb w/d pre-B cells; the levels of Myb affected the gene expression profile of p190 BCR/ABL -transformed cells the most, but a subset of genes was also modulated in normal B cells. We reasoned that among the genes differentially expressed in Myb w/f and Myb w/d p190 BCR/ABL -transformed pre-B cells there may be one or more whose change in expression is mechanistically linked to the impaired leukemogenic potential of Myb þ /À p190 BCR/ABLexpressing pre-B cells.
One such gene is Bmi1, which is an attractive candidate as a relevant c-Myb target because of its role in the self-renewal and maintenance of normal and leukemic stem cells, 25, 35 and its cooperation with classical oncogenes in neoplastic transformation. [36] [37] [38] [39] Through perturbation of gene expression, luciferase and ChIP assays we demonstrated that Bmi1 is a direct target of Myb; moreover, its ability to restore the defective colony formation of c-Myb w/d p190 BCR/ABL pre-B cells to levels Of equal importance, secondary colony formation of Bmi1transduced c-Myb w/d p190 BCR/ABL pre-B cells was also undistinguishable from that of Myb w/f p190 BCR/ABL -transformed pre-B cells, suggesting that high expression of Bmi1 is necessary for their self-renewal.
As normal pre-B cells possess limited self-renewal potential, p190BCR/ABL would not be able to maintain their transformed state had these cells not acquired self-renewal properties through a regulatory pathway dependent, in part, on increased Myb-Bmi1 expression.
Indeed, expression of c-Myb and Bmi1 was higher in p190 BCR/ABL -expressing pro-B and pre-B cells than in their normal counterpart ( Supplementary Figure 8) .
Although Bmi1 expression appears to be important for p190 BCR/ABL -dependent leukemogenesis, it is unlikely that it is the only relevant c-Myb target for maintenance of the transformed phenotype of p190 BCR/ABL -expressing B cells.
Bmi1-silenced p190 BCR/ABL marrow cells from transgenic mice formed fewer B-cell colonies than the control counterpart; although not directly comparable, c-Myb w/d p190 BCR/ABL B-cells were even less clonogenic than Bmi1-silenced p190 BCR/ABLexpressing cells, which would indicate that the consequences of reduced c-Myb expression for p190 BCR/ABL transformation of pre-B cells do not depend entirely on decreased Bmi1 levels.
The role of c-Myb and Bmi1 was also tested in p190 BCR/ABLexpressing Ph 1 ALL lines; proliferation and colony formation of Z-181 and SUP-B15 cells were suppressed by c-Myb or Bmi1 RNA interference, and Bmi1 levels were decreased in c-Mybsilenced cells, whereas c-Myb levels did not change in Bmi1-silenced cells.
Together, these findings suggest that expression of c-Myb and Bmi1 is functionally related, and that the c-Myb-Bmi1 pathway has an important role in regulating the proliferation and survival of Ph 1 ALL cells, although the effects of c-Myb may be, in part, Bmi1-independent and expression of Bmi1 may be regulated by other oncogenic proteins, including c-Myc. 30 A significant correlation between c-Myb and Bmi1 expression was noted in comparing c-Myb and Bmi1 mRNA levels in BCR/ABL-expressing ALL blasts; this finding is interesting because the expression of both genes is likely to be subjected to multiple regulatory mechanisms and their levels might be more closely related in clonogenic cells.
In summary, optimal levels of c-Myb expression are required for p190 BCR/ABL -dependent transformation and leukemogenesis, and the effects of c-Myb depend, in part, on its ability to enhance the expression of Bmi1, a gene that regulates the self-renewal of hematopoietic stem cells, 25, 35 endowing p190 BCR/ABL -transformed pro-and pre-B cells with 'stem cell properties' essential for leukemia maintenance.
